GAN Clinical Trials

308 recruitingLast updated: July 25, 2026

There are 308 actively recruiting gan clinical trials across 56 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1, Phase 4. Top locations include Philadelphia, Pennsylvania, United States, Boston, Massachusetts, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


GAN Trials at a Glance

308 actively recruiting trials for gan are listed on ClinicalTrialsFinder across 6 cities in 56 countries. The largest study group is Not Applicable with 92 trials, with the heaviest enrollment activity in Philadelphia, Boston, and Houston. Lead sponsors running gan studies include National Cancer Institute (NCI), Peking Union Medical College Hospital, and Novartis Pharmaceuticals.

Treatments under study

About GAN Clinical Trials

Looking for clinical trials for GAN? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new GAN trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about GAN clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 308 trials

Recruiting
Not Applicable

Spinal Mobilization With Arm Movement and Kaltenborn Mobilization in Adhesive Capsulitis

Adhesive CapsulitisShoulder PainSpinal Mobilization+2 more
Riphah International University50 enrolled2 locationsNCT07724691
Recruiting
Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled407 locationsNCT05675410
Recruiting
Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled251 locationsNCT06935357
Recruiting

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

ProlactinomaCushing DiseasePanhypopituitarism+1 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2,000 enrolled1 locationNCT00001595
Recruiting
Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled178 locationsNCT06172296
Recruiting
Phase 2

Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)

Metastatic Colorectal CancerFirst-line TreatmentOrganoids+3 more
St. Olavs Hospital148 enrolled1 locationNCT06907342
Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC355 enrolled84 locationsNCT04924075
Recruiting

Genome Transplant Dynamics

Thoracic Organ Transplantation
National Heart, Lung, and Blood Institute (NHLBI)991 enrolled6 locationsNCT02423070
Recruiting

Clinical and Laboratory Study of Methylmalonic Acidemia

Inborn Errors of MetabolismOrganic AcidemiaMethylmalonic Acidemia
National Human Genome Research Institute (NHGRI)2,275 enrolled3 locationsNCT00078078
Recruiting
Phase 2

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

GerminomaBasal Ganglia GerminomaDiabetes Insipidus+3 more
Children's Oncology Group240 enrolled114 locationsNCT06368817
Recruiting
Phase 1

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Malignant Neoplasm of Bone and Articular CartilageMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple Sites+7 more
M.D. Anderson Cancer Center44 enrolled1 locationNCT03093909
Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Gangliosidoses, GM2Gangliosidosis, GM1
Azafaros B.V.75 enrolled36 locationsNCT07082543
Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

GM1 GangliosidosisGM2 GangliosidosisNiemann-Pick Type C Disease
Azafaros B.V.147 enrolled38 locationsNCT07054515
Recruiting
Phase 3

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

IgA NephropathyImmunoglobulin A NephropathyBerger Disease+3 more
Novartis Pharmaceuticals28 enrolled6 locationsNCT07498335
Recruiting

Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia

Metabolic DiseaseOrganic AcidemiaPropionic Acidemia
National Human Genome Research Institute (NHGRI)1,045 enrolled2 locationsNCT02890342
Recruiting

Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies

Mortality in Sickle CellSickle Cell Cardiopulmonary ComplicationsSickle Cell Organ Damage+2 more
National Heart, Lung, and Blood Institute (NHLBI)200 enrolled1 locationNCT05213572
Recruiting
Phase 2

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

Classic Hodgkin LymphomaAdvanced Hodgkin LymphomaLugano Classification Stage III Hodgkin Lymphoma AJCC v8+1 more
University of Washington125 enrolled6 locationsNCT06745076
Recruiting
Phase 3

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Pyoderma Gangrenosum
Boehringer Ingelheim90 enrolled98 locationsNCT06624670
Recruiting

Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers

Environmental ExposureSDH Gene MutationSDH-Related Familial Paraganglioma+1 more
Assistance Publique - Hôpitaux de Paris1,300 enrolled20 locationsNCT06408402
Recruiting

GYNEMESH PS Mesh Post Marketing Clinical Follow-Up Study

pelvic organ prolapse
Ethicon, Inc.100 enrolled3 locationsNCT04829058